Frequency Therapeutics scores $62 mln Series C
Woburn, Massachusetts-based Frequency Therapeutics, a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, has raised $62 million in Series C financing. Perceptive Advisors led the round.
24 July 2019•1 min read
